Terumo Ends Boston Scientific Deal to Start Urology Unit
Terumo Corp., Asia’s biggest maker of medical devices, plans to end a urology partnership with Boston Scientific Corp. in the U.S. and create its own sales, marketing and distribution unit for the products in April.
Creating the urology unit will provide better access to a U.S. market estimated to generate $2.3 billion in sales by 2016, the Tokyo-based company said in a statement today. The Terumo Interventional Systems unit sells devices including guidewires and catheters that give doctors access to the heart and peripheral blood vessels to treat disease.
Terumo ended a similar relationship with Natick, Massachusetts-based Boston Scientific for heart devices in 2006. Terumo’s Glidewire products are used in one-third of minimally invasive urological procedures each year in the U.S., such as the treatment of kidney stones. About 685,000 Americans annually are treated for kidney stones, the accumulation of hard and painful crystals inside the kidneys.
“We are committed to meeting the growing demands of this important customer base,” said James Rushworth, president of Terumo Interventional Systems and the Onset Medical unit that the company purchased in January 2012 for its sheath technology. “Terumo Interventional Systems plans to introduce a steady stream of devices inspired by clinical performance, economic advantages, and improved quality of life for patients.”
To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com